PSY10 ADHD

Descrição

PHCY320 (Psychiatry) Quiz sobre PSY10 ADHD, criado por Mer Scott em 13-10-2019.
Mer Scott
Quiz por Mer Scott, atualizado more than 1 year ago
Mer Scott
Criado por Mer Scott aproximadamente 5 anos atrás
1
0

Resumo de Recurso

Questão 1

Questão
Epidemiology of ADHD • Historically viewed as a childhood disorder only but that’s changed with [blank_start]3-7%[blank_end] of school age children diagnosed globally, in adults ~ half that • Increased incidence of [blank_start]depression[blank_end], ~14% of those who are 6-17 years old, some studies demonstrated in up to 50% of adolescents • Adults with ADHD also show early onset of depression, increased [blank_start]morbidity[blank_end] and severity plus a higher [blank_start]suicide[blank_end] rate compared to adults without ADHD • Treatment of depression with comorbid ADHD generally more [blank_start]difficult[blank_end], treatment-resistance is more common • Childhood ADHD is sometimes the early expression of an emergent [blank_start]bipolar disorder[blank_end] • 10 - 20% of adults with bipolar disorder have comorbid [blank_start]ADHD[blank_end]
Responda
  • 3-7%
  • depression
  • morbidity
  • suicide
  • difficult
  • bipolar disorder
  • ADHD

Questão 2

Questão
Children and adolescents: Easy to diagnose, [blank_start]High[blank_end] levels of identification, and Tx > 50%, stimulants used [blank_start]first and second[blank_end] line Adults: Hard to diagnose (inaccurate retrospective recall of [blank_start]onset[blank_end]). Late onset, same [blank_start]genetics, comorbidity and impairments[blank_end]. [blank_start]Low[blank_end] levels of identification, and Tx < 20%. Stimulants [blank_start]not[blank_end] first line.
Responda
  • high
  • first and second
  • onset
  • genetics, comorbidity and impairments
  • Low
  • not

Questão 3

Questão
DSM-V Diagnosis Noted trio of symptoms i.e. inattention (selective and sustained), hyperactivity and impulsivity. - Inattention: -- Sustained attention: Hypothetically modulated by connections between the [blank_start]dorsolateral prefrontal cortex (DLPFC)[blank_end] projecting to the striatal complex, the thalamus and back. Inefficient activation leads to difficulty following through/[blank_start]finishing[blank_end] tasks, dis[blank_start]organization[blank_end] and trouble sustaining mental [blank_start]effort[blank_end]. -- Selective attention: Hypothetically modulated by connections between the [blank_start]dorsal anterior cingulate cortex (dACC)[blank_end] which projects to the striatal complex, then thalamus and back to the dACC. Inefficient activation of the [blank_start]dACC[blank_end] results in symptoms such as decreased attention to [blank_start]detail[blank_end], careless mistakes, not listening, [blank_start]losing[blank_end]things, being [blank_start]distracted[blank_end] and forgetting. - Hyperactivity and impulsivity Often fidgets, squirm, is restless, can't stay [blank_start]seated[blank_end], difficulty playing [blank_start]quietly[blank_end], [blank_start]interrupts[blank_end] or intrudes on others; may take over what others are doing • [blank_start]Six[blank_end] or more symptoms must be present for at least 6 [blank_start]months[blank_end]; [blank_start]five[blank_end] symptoms required in older adolescents and adults (> 17 years of age) • Significant impairment must be seen in two or more settings (e.g. home and school); symptoms must be documented by parent, teacher, and clinician.
Responda
  • dorsolateral prefrontal cortex (DLPFC)
  • finishing
  • organization
  • effort
  • dorsal anterior cingulate cortex (dACC)
  • dACC
  • detail
  • losing
  • distracted
  • seated
  • quietly
  • interrupts
  • Six
  • months
  • five

Questão 4

Questão
Match the symptoms to the regions: Dorsal ACC - [blank_start]selective attention[blank_end] Prefrontal cortex (PFC) - [blank_start]hyperactivity[blank_end] Dorsolateral prefrontal cortex (DLPFC) - [blank_start]sustained attention[blank_end] Orbitofrontal cortex - [blank_start]impulsivity[blank_end]
Responda
  • selective attention
  • sustained attention
  • hyperactivity
  • impulsivity

Questão 5

Questão
Causes? • Familial and [blank_start]genetic[blank_end] association • Synaptogenesis in [blank_start]PFC[blank_end] might be responsible... -At 6-7 years, [blank_start]sustained[blank_end] attention and planning begin to develop. This age is characterized by “[blank_start]synaptic pruning,[blank_end]” i.e. overproduced or “weak” synapses are “weeded out,” which allows [blank_start]cognitive intelligence[blank_end] to mature. Errors in this [blank_start]process[blank_end] could hypothetically affect further development of executive function and could be a cause of ADHD. ADHD symptoms in children often appear around [blank_start]6[blank_end] years of age.
Responda
  • genetic
  • PFC
  • sustained
  • synaptic pruning
  • cognitive intelligence
  • process
  • 6

Questão 6

Questão
Hyperactivity and impulsivity are key symptoms in childhood, while inattention becomes prevalent with age.
Responda
  • True
  • False

Questão 7

Questão
Impulsivity • Associated with reciprocal connections between the [blank_start]orbitofrontal cortex (OFC)[blank_end], the striatal complex, and the thalamus. Hyperactivity and psychomotor agitation/retardation • Modulated by cortico-striato-thalamo-cortical ([blank_start]CSTC[blank_end]) loop from the [blank_start]PFC[blank_end] to the [blank_start]lateral[blank_end] striatum, to the thalamus and back to the PFC.
Responda
  • orbitofrontal cortex (OFC)
  • CSTC
  • PFC
  • lateral

Questão 8

Questão
Choose the correct statement.
Responda
  • Alterations within the prefrontal cortex (PFC) hypothesized to lead to problems with impulsivity or hyperactivity
  • Inadequate ‘tuning’ of the DLPFC or the dACC can respectively lead to deficits in sustained or selective attention

Questão 9

Questão
Comorbidities • Result of [blank_start]similar or additional[blank_end] deficits within the ventromedial prefrontal cortex – [blank_start]limbic[blank_end] system • Many [blank_start]mood[blank_end] disorders comorbid with ADHD in children and adults • Symptoms in adults more disabling if comorbidities were already present in the [blank_start]child[blank_end]. Reinforces the importance of treating all symptoms in young patients to maximize their chances of a “regular” adult life • Oppositional defiant or [blank_start]Conduct[blank_end] disorder occur in 30-[blank_start]60[blank_end]% of youth diagnosed with ADHD • Childhood comorbidities include depression, [blank_start]Autism[blank_end] spectrum disorders, childhood [blank_start]bipolar[blank_end] disorder
Responda
  • similar or additional
  • limbic
  • mood
  • child
  • Conduct
  • 60
  • Autism
  • bipolar

Questão 10

Questão
As deficient [blank_start]arousal in the PRC[blank_end] is the main problem in ADHD, drugs to treat it either: 1. increase the [blank_start]release of DA and NA[blank_end] or 2. increase tonic [blank_start]firing of the neurons[blank_end] increases prefrontal activity to an optimal level Hypothetically, if DA and NA levels are to low, low [blank_start]NA[blank_end] causes reduced '[blank_start]signal[blank_end]' and low [blank_start]DA[blank_end] causes increased '[blank_start]noise[blank_end]'. Inability to sit still and focus are manifestations of the imbalanced signal-to-noise ratio. Treatment increases [blank_start]signal strength output[blank_end] by increasing the [blank_start]concentration[blank_end] of both DA and NA until they reach the optimal dose.
Responda
  • arousal in the PRC
  • release of DA and NA
  • firing of the neurons
  • NA
  • signal
  • DA
  • noise
  • signal strength output
  • concentration

Questão 11

Questão
Methylphenidate(stimulant) / Vitamin R: - increase release of DA in the [blank_start]NAc[blank_end] (nucleus accumbens) and - increase release of NA and DA in the [blank_start]PFC[blank_end] by [blank_start]blocking blocking[blank_end] reuptake pumps (NAT and DAT). Unlike amphetamine, [blank_start]methylphenidate[blank_end] is not taken up into the [blank_start]DA terminal[blank_end] via the transporter and is not a [blank_start]competitive[blank_end] inhibitor.
Responda
  • NAc
  • PFC
  • blocking
  • methylphenidate
  • DA terminal
  • competitive

Questão 12

Questão
Amphetamine: Competitive inhibitor- 1) at [blank_start]DAT[blank_end] which competes with DA 2) at [blank_start]NAT[blank_end] which competes with NA Also competitive inhibitor of the [blank_start]VMAT[blank_end] (methylphenidate is [blank_start]not[blank_end]) = taken into the [blank_start]DA terminal[blank_end] via the DAT, where it's packaged into [blank_start]vesicles[blank_end]. At [blank_start]high[blank_end] levels, it also [blank_start]displaces[blank_end] DA from the vesicles into the terminal. Once a critical [blank_start]threshold[blank_end] of DA is reached, DA is expelled from terminaml by opening [blank_start]channels[blank_end] to allow [blank_start]large[blank_end] scale release into the [blank_start]synapse[blank_end] and reversal of the [blank_start]DAT[blank_end]! This rapid release of DA leads to the [blank_start]euphoria[blank_end] experienced by amphetamine users.
Responda
  • DAT
  • NAT
  • VMAT
  • not
  • DA terminal
  • vesicles
  • displaces
  • high
  • threshold
  • channels
  • large
  • synapse
  • DA transporter (DAT)
  • euphoria

Questão 13

Questão
Dexamphetamine • Competitive inhibitor at [blank_start]DAT, NET,[blank_end] and the [blank_start]Vesicular Monoamine Transporter[blank_end] (VMAT) - competes with Da and NA • Unlike methylphenidate, which is not taken [blank_start]into the cell[blank_end] • [blank_start]d-isomer[blank_end] more effective than [blank_start]l-isomer[blank_end] for DAT binding • d- and l-isomers are equipotent for [blank_start]NAT[blank_end] binding
Responda
  • DAT, NAT,
  • Vesicular Monoamine Transporter
  • into the cell
  • d-isomer
  • l-isomer
  • NAT

Questão 14

Questão
Common Stimulant Adverse effects: 1. [blank_start]Reduced appetite, weight loss[blank_end] Have a high-calorie meal when stimulant effects are low (at breakfast or at bedtime), or consider cyproheptadine (antihistamine) at bedtime 2. [blank_start]Stomach-ache[blank_end] Give on a full stomach; lower dose if possible 3. [blank_start]Insomnia[blank_end] Give earlier in the day; decrease last dose of the day, consider a hypnotic at bedtime e.g. clonidine, melatonin, or cyproheptadine. 4. [blank_start]Headache[blank_end] Divide dose, give with food, or give analgesic 5. [blank_start]Rebound symptoms[blank_end] Consider longer-acting stimulant trial, atomoxetine, or antidepressant 6. [blank_start]Irritability/jitteriness[blank_end] Assess for comorbid condition e.g. bipolar disorder; reduce dose; consider mood stabilizer or atypical antipsychotic
Responda
  • Reduced appetite, weight loss
  • Stomach-ache
  • Insomnia
  • Headache
  • Rebound symptoms
  • Irritability/jitteriness

Questão 15

Questão
Atomoxetine • Selective [blank_start]NA reuptake inhibitor (NRI)[blank_end], also an antidepressant • Since the PFC lacks [blank_start]high[blank_end] concentrations of the DAT, [blank_start]DA[blank_end] is inactivated there by the [blank_start]NAT[blank_end] (promiscuous). So, blocking NAT will increase [blank_start]both DA and NA[blank_end] levels in the PFC • The relative [blank_start]lack[blank_end] of NAT in the [blank_start]NAc[blank_end] prevents atomoxetine from [blank_start]increasing[blank_end] NA or DA levels in that region → reduced risk of [blank_start]abuse[blank_end] Bupropion - Not selective, is a [blank_start]noradrenaline - dopamine[blank_end] reuptake inhibitor or [blank_start]NDRI[blank_end] - Effective for the treatment of ADHD and depression - Preferred for [blank_start]older[blank_end] patients due to comorbid substance abuse or depression
Responda
  • NA reuptake inhibitor (NRI)
  • NDRI
  • noradrenaline - dopamine
  • high
  • DA
  • NAT
  • both DA and NA
  • lack
  • NAc
  • increasing
  • abuse
  • older

Questão 16

Questão
Relative effects • [blank_start]Atomoxetine[blank_end] - slower onset than stimulants - 2–4 weeks v’s 1–2 hours, full benefit might take [blank_start]6-12 weeks[blank_end] • Gender - males having increased [blank_start]methylphenidate bioavailability[blank_end] compared to females • Dose [blank_start]variability[blank_end] for all of mentioned meds, can be due to inter-individual variability in plasma concentration. • All metabolized by CYP2D6 so [blank_start]bupropion, fluoxetine, or paroxetine[blank_end] can increase biavailability by [blank_start]4-8[blank_end] times • Atomoxetine - [blank_start]CYP2D6 poor metabolizers[blank_end] may experience more insomnia, weight loss, increased HR and BP constipation and depression compared to extensive metabolizers BUT might also have [blank_start]better[blank_end] therapeutic benefit • Small increase in [blank_start]HR and BP[blank_end] on 1-2% of children • No effect on liability for substance abuse with increasing age, possibly [blank_start]protective[blank_end] if started < [blank_start]8[blank_end] years of age
Responda
  • 6-12 weeks
  • Atomoxetine
  • methylphenidate bioavailability
  • variability
  • bupropion, fluoxetine, or paroxetine
  • 4-8
  • CYP2D6 poor metabolizers
  • better
  • HR and BP
  • protective
  • 8

Semelhante

Mental health chapter 10
nursing fairy
Mental State Exam
Matthew Coulson
Perinatal Psychiatry
Matthew Coulson
Psychiatry Genetics
Matthew Coulson
Eating Disorders
Matthew Coulson
Neurobiology of Addiction
Matthew Coulson
Addictive behaviour
Megan Kerr
Behavioral Neuroscience
Tambriell Caudill
Introduction to Psychology
Skye Chen
Liaison Psychiatry
Vishnu Pradeep
Perinatal Psychiatry
Kit Grissett